Uvantis Therapeutics, Inc.
New Filing
CIK: 0002156954·Biotechnology·DELAWARE·Filed: Sep 23, 2026
Total Offering
$5,000,000
Amount Sold
$100,000
Investors
1
First Sale
Sep 10, 2026
Offering Details
- Type
- Debt, Option to Acquire
- Exemptions
- Rule 506(b)
- Entity Type
- Corporation
- Year Incorporated
- 2025
- Non-Accredited Investors
- No
Related Persons
| Name | Role |
|---|---|
| William Sheahan | |
| Jonathan Young | |
| Edward Woo | |
| Paul Giannasca | |
| Jeffrey Collins |
Company
SEC Filing
0002156954-26-000001
View on SEC EDGARWant deeper insights?
Sign up for free to search all filings, track companies, and set up alerts.
Sign Up Free